Barbara Lenzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4378596/publications.pdf Version: 2024-02-01



RADRADA LENZI

#	Article	IF	CITATIONS
1	Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case report. Annals of Palliative Medicine, 2021, 10, 8474-8478.	1.2	0
2	Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. Anti-Cancer Drugs, 2020, 31, 1103-1105.	1.4	5
3	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2019, 17, 1388-1397.e1.	4.4	16
4	Response to Intermediate stage treatment: Is TACE enough?. Liver International, 2018, 38, 188-189.	3.9	1
5	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	7.3	93
6	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	3.9	46
7	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	3.9	67
8	De novo hepatocellular carcinoma of liver allograft: A neglected issue. Cancer Letters, 2015, 357, 47-54.	7.2	27
9	<scp>QT</scp> interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver International, 2012, 32, 1510-1515.	3.9	48